www.usmedschoice.com

Warning LetterOpen

www.usmedschoice.com United StatesIssued Oct 6, 2025Center for Drug Evaluation and Research (CDER)

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations3

Issue DateOct 6, 2025

Product TypeDrugs

StatusOpen

Letter Details

Firm: www.usmedschoice.com
Location: www.usmedschoice.com United States
FEI Number: N/A
Country: United States
Issue Date: October 06, 2025
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Summary

www.usmedschoice.com was found to be unlawfully selling unapproved and misbranded drugs over the internet, including opioids, benzodiazepines, and Schedule II stimulants, in violation of sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The FDA cited particular concern regarding the public health risks posed by the online availability of these high-risk drug products, given the ongoing opioid epidemic, the abuse potential of benzodiazepines (especially when co-used with other substances), and the diversion risk of Schedule II stimulants. The company failed to obtain FDA approval for these new drugs and failed to properly label them as required by law before introducing them into interstate commerce.